255 related articles for article (PubMed ID: 33425745)
21. The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade.
Foy JP; Bertolus C; Michallet MC; Deneuve S; Incitti R; Bendriss-Vermare N; Albaret MA; Ortiz-Cuaran S; Thomas E; Colombe A; Py C; Gadot N; Michot JP; Fayette J; Viari A; Van den Eynde B; Goudot P; Devouassoux-Shisheboran M; Puisieux A; Caux C; Zrounba P; Lantuejoul S; Saintigny P
Ann Oncol; 2017 Aug; 28(8):1934-1941. PubMed ID: 28460011
[TBL] [Abstract][Full Text] [Related]
22. CD8A as a Prognostic and Immunotherapy Predictive Biomarker Can Be Evaluated by MRI Radiomics Features in Bladder Cancer.
Zheng Z; Guo Y; Huang X; Liu J; Wang R; Qiu X; Liu S
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230788
[TBL] [Abstract][Full Text] [Related]
23. Indoleamine 2,3-dioxygenase 1 and overall survival of patients diagnosed with esophageal cancer.
Rosenberg AJ; Wainwright DA; Rademaker A; Galvez C; Genet M; Zhai L; Lauing KL; Mulcahy MF; Hayes JP; Odell DD; Horbinski C; Komanduri S; Tetreault MP; Kim KA; Villaflor VM
Oncotarget; 2018 May; 9(34):23482-23493. PubMed ID: 29805749
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive analysis of EML2 as a prognostic biomarker in colon cancer.
Sun Y; Han L; Sun D
Int J Clin Exp Pathol; 2024; 17(1):1-12. PubMed ID: 38322176
[TBL] [Abstract][Full Text] [Related]
25. IDO1 as a new immune biomarker for diabetic nephropathy and its correlation with immune cell infiltration.
Yu K; Li D; Xu F; Guo H; Feng F; Ding Y; Wan X; Sun N; Zhang Y; Fan J; Liu L; Yang H; Yang X
Int Immunopharmacol; 2021 May; 94():107446. PubMed ID: 33581581
[TBL] [Abstract][Full Text] [Related]
26. Investigation of indoleamine 2,3-dioxygenase 1 expression in uveal melanoma.
Liang C; Peng L; Zeng S; Zhao Q; Tang L; Jiang X; Zhang J; Yan N; Chen Y
Exp Eye Res; 2019 Apr; 181():112-119. PubMed ID: 30639792
[TBL] [Abstract][Full Text] [Related]
27. Peptide vaccination directed against IDO1-expressing immune cells elicits CD8
Dey S; Sutanto-Ward E; Kopp KL; DuHadaway J; Mondal A; Ghaban D; Lecoq I; Zocca MB; Merlo LMF; Mandik-Nayak L; Andersen MH; Pedersen AW; Muller AJ
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690770
[TBL] [Abstract][Full Text] [Related]
28. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
Wu P; Zheng Y; Wang Y; Wang Y; Liang N
J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
[TBL] [Abstract][Full Text] [Related]
29. Increased expression of IDO1 is associated with improved survival and increased number of TILs in patients with high-grade serous ovarian cancer.
Hoffmann I; Dragomir MP; Monjé N; Keunecke C; Kunze CA; Schallenberg S; Marchenko S; Schmitt WD; Kulbe H; Sehouli J; Braicu IE; Jank P; Denkert C; Darb-Esfahani S; Horst D; Sinn BV; Sers C; Bischoff P; Taube ET
Neoplasia; 2023 Oct; 44():100934. PubMed ID: 37703626
[TBL] [Abstract][Full Text] [Related]
30. Indoleamine-2,3-dioxygenase-1 expression predicts poorer survival and up-regulates ZEB2 expression in human early stage bladder cancer.
Tsai YS; Jou YC; Tsai HT; Cheong IS; Tzai TS
Urol Oncol; 2019 Nov; 37(11):810.e17-810.e27. PubMed ID: 31253481
[TBL] [Abstract][Full Text] [Related]
31. Identification and validation of xenobiotic metabolism-associated prognostic signature based on five genes to evaluate immune microenvironment in colon cancer.
Wen L; Han Z
J Gastrointest Oncol; 2021 Dec; 12(6):2788-2802. PubMed ID: 35070407
[TBL] [Abstract][Full Text] [Related]
32. Identification of Novel Immunologic Checkpoint Gene Prognostic Markers for Ovarian Cancer.
Huo X; Zhang X; Li S; Wang S; Sun H; Yang M
J Oncol; 2022; 2022():8570882. PubMed ID: 36157232
[TBL] [Abstract][Full Text] [Related]
33. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
Zuo S; Wei M; Wang S; Dong J; Wei J
Front Immunol; 2020; 11():1218. PubMed ID: 32714316
[No Abstract] [Full Text] [Related]
34. High expression of immune checkpoints is associated with the TIL load, mutation rate and patient survival in colorectal cancer.
Kitsou M; Ayiomamitis GD; Zaravinos A
Int J Oncol; 2020 Jul; 57(1):237-248. PubMed ID: 32468013
[TBL] [Abstract][Full Text] [Related]
35. Hypoxic Characteristic in the Immunosuppressive Microenvironment of Hepatocellular Carcinoma.
Mo Z; Liu D; Rong D; Zhang S
Front Immunol; 2021; 12():611058. PubMed ID: 33679749
[No Abstract] [Full Text] [Related]
36. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
[TBL] [Abstract][Full Text] [Related]
37. Identification and validation of the prognostic value of cyclic GMP-AMP synthase-stimulator of interferon (cGAS-STING) related genes in gastric cancer.
Yang KS; Xu CQ; Lv J
Bioengineered; 2021 Dec; 12(1):1238-1250. PubMed ID: 33843442
[TBL] [Abstract][Full Text] [Related]
38. ARID5A stabilizes Indoleamine 2,3-dioxygenase expression and enhances CAR T cell exhaustion in colorectal cancer.
Wu D; Wang G; Wen S; Liu X; He Q
Transl Oncol; 2024 Apr; 42():101900. PubMed ID: 38316094
[TBL] [Abstract][Full Text] [Related]
39. Programmed death ligand 1/indoleamine 2,3-dioxygenase 1 expression and tumor-infiltrating lymphocyte status in renal cell carcinoma with sarcomatoid changes and rhabdoid features.
Kiyozawa D; Takamatsu D; Kohashi K; Kinoshita F; Ishihara S; Toda Y; Eto M; Oda Y
Hum Pathol; 2020 Jul; 101():31-39. PubMed ID: 32360490
[TBL] [Abstract][Full Text] [Related]
40. Three Immune-Associated Subtypes of Diffuse Glioma Differ in Immune Infiltration, Immune Checkpoint Molecules, and Prognosis.
Zhou Q; Yan X; Liu W; Yin W; Xu H; Cheng D; Jiang X; Ren C
Front Oncol; 2020; 10():586019. PubMed ID: 33425739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
